화학요법 유발성 빈혈 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 치료 유형별, 약제 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Chemotherapy-Induced Anemia (CIA) Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.31 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.02% during the forecast period. The market for chemotherapy-induced anemia has become a significant focus within the oncology sector, with chemotherapy being a primary treatment for cancer patients. As chemotherapy use continues to rise, the prevalence of chemotherapy-induced anemia has concurrently increased. This condition not only impacts cancer patients' quality of life but also presents substantial business opportunities for pharmaceutical companies and healthcare providers.

Chemotherapy-induced anemia is a common side effect of chemotherapy, occurring when chemotherapy drugs impair the bone marrow's ability to produce red blood cells, thereby reducing hemoglobin levels in the blood. This condition can result in symptoms such as fatigue, weakness, shortness of breath, and a reduced tolerance for further cancer treatments. As a result, the management of CIA has become a key aspect of cancer care, leading to increased demand for effective treatments.

CIA affects a wide range of cancer patients, with the American Cancer Society reporting that 30-90% of cancer patients undergoing chemotherapy experience varying degrees of anemia. Treatments for CIA include erythropoiesis-stimulating agents (ESAs), iron supplements, blood transfusions, and emerging therapies. ESAs, including erythropoietin-stimulating agents and darbepoetin alfa, have been commonly used to manage the condition, although safety concerns and regulatory changes have impacted their usage. Key players in the CIA market include major pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche, which are developing and marketing treatments for this condition.

The CIA market is dynamic, presenting both challenges and opportunities. Regulatory concerns and reimbursement issues pose significant hurdles, but ongoing research, patient-centered care, industry collaboration, and market expansion offer a promising future. As the healthcare industry continues to prioritize cancer patient well-being, advancements in CIA management will be crucial to improving the quality of life for those undergoing chemotherapy. Pharmaceutical companies and healthcare providers must remain agile and innovative to meet the needs of this growing patient population.

Key Market Drivers

Increasing Incidence of Cancer: The global incidence of cancer is a significant driver of the chemotherapy-induced anemia market. As cancer cases continue to rise, so does the demand for effective treatments, including chemotherapy. Despite its effectiveness, chemotherapy is associated with side effects such as CIA, which is gaining increased attention. The rising cancer incidence is prompting research, innovation, and the development of therapies to manage this condition.

According to the World Cancer Research Fund, there were 19,976,499 cancer cases worldwide in 2022, including non-melanoma skin cancer. Excluding non-melanoma skin cancer, the number of cases was 18,741,966, with nearly equal distribution between men (9,566,825 cases) and women (9,175,141 cases).

Key Market Challenges

Regulatory Barriers: Regulatory hurdles pose significant challenges for companies in the CIA market. Navigating the complex regulatory environment requires substantial resources and time. Regulatory agencies, including the FDA and EMA, require extensive preclinical and clinical data to evaluate the safety and efficacy of new therapies. This process is often lengthy and costly, delaying time to market and increasing financial strain for companies. Regulatory requirements also vary across regions, further complicating international market expansion. Smaller firms, in particular, face challenges competing with larger, more established companies with greater resources and experience in managing regulatory processes.

Key Market Trends

Rising Awareness and Early Diagnosis of Chemotherapy-Induced Anemia: Increasing awareness and early diagnosis of CIA is a major driver of the global market. As cancer incidence grows and treatment regimens become more complex, there is greater recognition of the impact of chemotherapy-induced anemia on patients' quality of life. Previously underdiagnosed or underappreciated, CIA is now receiving more attention from healthcare professionals, leading to an increased demand for treatment options.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd.
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

Report Scope

This report segments the Global Chemotherapy-Induced Anemia Market as follows:

By Disease Type:

• Mild Anemia
• Moderate Anemia
• Severe Anemia

By Treatment Type:

• RBC Transfusions
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplementation

By Drug Type:

• Epogen Injection
• Procrit Injection
• Androxy Oral
• Aranesp Injection
• Epoetin Alfa Injection
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the major companies operating in the Chemotherapy-Induced Anemia Market.

Available Customizations

The Global Chemotherapy-Induced Anemia market report offers the following customizations tailored to the needs of specific companies:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy-Induced Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia)
  • 5.2.2. By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation)
  • 5.2.3. By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy-Induced Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy-Induced Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Chemotherapy-Induced Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Chemotherapy-Induced Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By End User

7. Europe Chemotherapy-Induced Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy-Induced Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Chemotherapy-Induced Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Chemotherapy-Induced Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By End User
  • 7.3.4. France Chemotherapy-Induced Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Chemotherapy-Induced Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Chemotherapy-Induced Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy-Induced Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Chemotherapy-Induced Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Chemotherapy-Induced Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Chemotherapy-Induced Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Chemotherapy-Induced Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By End User

9. South America Chemotherapy-Induced Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy-Induced Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Chemotherapy-Induced Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Chemotherapy-Induced Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Chemotherapy-Induced Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy-Induced Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Chemotherapy-Induced Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Chemotherapy-Induced Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Dr. Reddy's Laboratories Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Panacea Biotec Limited
• 14.4. SBI Pharmaceuticals Co., Ltd
• 14.5. Sumitomo Dainippon Pharma Co., Ltd.
• 14.6. PharmaEssentia Corp.
• 14.7. PhytoHealth Corp
• 14.8. UBI Pharma Inc.
• 14.9. Amgen Inc.
• 14.10. Astellas Pharma Inc.

15. Strategic Recommendations

16. About Us & Disclaimer